The EMT-activator Zeb1 is a key factor for cell plasticity and promotes metastasis in pancreatic cancer

Nature Cell Biology

Volumn 19, Issue 5, 2017, Pages 518-529

  Krebs, Angela M ^a,b,c   Mitschke, Julia ^d   Losada, María Lasierra ^a   Schmalhofer, Otto ^d   Boerries, Melanie ^b,c   Busch, Hauke ^b,c   Boettcher, Martin ^e   Mougiakakos, DImitrios ^e   Reichardt, Wilfried ^c,d   Bronsert, Peter ^c,d   Brunton, Valerie G ^f   Pilarsky, Christian ^e   Winkler, Thomas H ^a   Brabletz, Simone ^a   Stemmler, Marc P ^a   Brabletz, Thomas ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^d UNIVERSITY OF FREIBURG   (Germany)

^e UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^f UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53; SHORT HAIRPIN RNA; TRANSCRIPTION FACTOR GATA 6; TRANSCRIPTION FACTOR PDX 1; TRANSCRIPTION FACTOR SOX2; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR; HOMEODOMAIN PROTEIN; KRAS2 PROTEIN, MOUSE; NUCLEAR PROTEIN; PANCREATIC AND DUODENAL HOMEOBOX 1 PROTEIN; PROTEIN P21; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR SNAIL; TWIST RELATED PROTEIN 1; TWIST1 PROTEIN, MOUSE; ZEB1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CELL PLASTICITY; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIAL MESENCHYMAL TRANSITION; GENE SILENCING; GLYCOLYSIS; HISTOPATHOLOGY; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LUNG METASTASIS; MICROARRAY ANALYSIS; MOUSE; MTT ASSAY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OXIDATIVE PHOSPHORYLATION; OXYGEN CONSUMPTION; PANCREAS CANCER; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR INVASION; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; CELL MOTION; CELL PROLIFERATION; EXPERIMENTAL NEOPLASM; GENETIC PREDISPOSITION; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; MUTATION; PANCREAS TUMOR; PATHOLOGY; RNA INTERFERENCE; SECONDARY; SIGNAL TRANSDUCTION; TIME FACTOR; TRANSGENIC MOUSE; TUMOR CELL CULTURE; TUMOR SUPPRESSOR GENE;

ANIMALS; CELL MOVEMENT; CELL PLASTICITY; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENES, P53; GENETIC PREDISPOSITION TO DISEASE; HOMEODOMAIN PROTEINS; HUMANS; LUNG NEOPLASMS; MICE, TRANSGENIC; MUTATION; NEOPLASMS, EXPERIMENTAL; NUCLEAR PROTEINS; PANCREATIC NEOPLASMS; PHENOTYPE; PROTO-ONCOGENE PROTEINS P21(RAS); RNA INTERFERENCE; SIGNAL TRANSDUCTION; SNAIL FAMILY TRANSCRIPTION FACTORS; TIME FACTORS; TRANS-ACTIVATORS; TRANSFECTION; TUMOR BURDEN; TUMOR CELLS, CULTURED; TWIST-RELATED PROTEIN 1; ZINC FINGER E-BOX-BINDING HOMEOBOX 1;

EID: 85017499836     PISSN: 14657392     EISSN: 14764679     Source Type: Journal    
DOI: 10.1038/ncb3513     Document Type: Article

References (70)

1. Brabletz, T. To differentiate or not - routes towards metastasis. Nat. Rev. Cancer 12, 425-436 (2012).
2. Kalluri, R. &Weinberg, R. A. The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420-1428 (2009).
3. Nieto, M. A., Huang, R. Y.-J., Jackson, R. A. & Thiery, J. P. EMT: 2016. Cell 166, 21-45 (2016).
4. Brabletz, S. & Brabletz, T. The ZEB/miR-200 feedback loop - a motor of cellular plasticity in development and cancer? EMBO Rep. 11, 670-677 (2010).
5. Vandewalle, C., Van Roy, F. & Berx, G. The role of the ZEB family of transcription factors in development and disease. Cell. Mol. Life Sci. 66, 773-787 (2009).
6. Zhang, P., Sun, Y. & Ma, L. ZEB1: at the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle 14, 481-487 (2015).
7. Fischer, K. R. et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527, 472-476 (2015).
8. Zheng, X. et al. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527, 525-530 (2015).
9. Hingorani, S. R. et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
10. Rhim, A. D. et al. EMT and dissemination precede pancreatic tumor formation. Cell 148, 349-361 (2012).
11. Higashi, Y. et al. Impairment of T Cell Development in deltaEF1 Mutant Mice. J. Exp. Med. 185, 1467-1480 (1997).
12. Brabletz, S. et al. Generation and characterization of mice for conditional inactivation of Zeb1. Genesis http://dx.doi.org/10.1002/dvg.23024 (2017).
13. Martinelli, P. et al. GATA6 regulates EMT and tumour dissemination, and is a marker of response to adjuvant chemotherapy in pancreatic cancer. Gut http://dx.doi.org/10.1136/gutjnl-2015-311256 (2016).
14. Laklai, H. et al. Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression. Nat. Med. 22, 497-505 (2016).
15. Erkan, M. et al. The activated stroma index is a novel and independent prognostic marker in pancreatic ductal adenocarcinoma. Clin. Gastroenterol. Hepatol. 6, 1155-1161 (2008).
16. Özdemir, B. C. et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell 25, 719-734 (2014).
17. Rhim, A. D. et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell 25, 735-747 (2014).
18. Tsai, J. H., Donaher, J. L., Murphy, D. A., Chau, S. & Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22, 725-736 (2012).
19. Ocaña, O. H. et al. Metastatic colonization requires the repression of the epithelialmesenchymal transition inducer Prrx1. Cancer Cell 22, 709-724 (2012).
20. Korpal, M. et al. Direct targeting of Sec23a by miR-200s influences cancer cell secretome and promotes metastatic colonization. Nat. Med. 17, 1101-1108 (2011).
21. Raj, D., Aicher, A. & Heeschen, C. Concise review: stem cells in pancreatic cancer: from concept to translation. Stem Cells 33, 2893-2902 (2015).
22. Vannier, C., Mock, K., Brabletz, T. & Driever, W. Zeb1 regulates E-cadherin and Epcam (epithelial cell adhesion molecule) expression to control cell behavior in early zebrafish development. J. Biol. Chem. 288, 18643-18659 (2013).
23. Dosch, J. S., Ziemke, E. K., Shettigar, A., Rehemtulla, A. & Sebolt-Leopold, J. S. Cancer stem cell marker phenotypes are reversible and functionally homogeneous in a preclinical model of pancreatic cancer. Cancer Res. 75, 4582-4592 (2015).
24. Wellner, U. et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat. Cell Biol. 11, 1487-1495 (2009).
25. Herreros-Villanueva, M. et al. SOX2 promotes dedifferentiation and imparts stem celllike features to pancreatic cancer cells. Oncogenesis 2, e61 (2013).
26. Sanada, Y. et al. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas 32, 164-170 (2006).
27. Singh, S. K. et al. Antithetical NFATc1-Sox2 and p53-miR200 signaling networks govern pancreatic cancer cell plasticity. EMBO J. 34, 517-530 (2015).
28. Muller, P. A. J. & Vousden, K. H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25, 304-317 (2014).
29. Rivlin, N., Koifman, G. & Rotter, V. p53 orchestrates between normal differentiation and cancer. Semin. Cancer Biol. 32, 10-17 (2015).
30. Morton, J. P. et al. Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer. Proc. Natl Acad. Sci. USA 107, 246-251 (2010).
31. Lehmann, W. et al. ZEB1 turns into a transcriptional activator by interacting with YAP1 in aggressive cancer types. Nat. Commun. 7, 10498 (2016).
32. Mock, K. et al. The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget 6, 14399-14412 (2015).
33. Brabletz, S. et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J. 30, 770-782 (2011).
34. Singh, A. et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 15, 489-500 (2009).
35. Nakamura, T., Fidler, I. J. & Coombes, K. R. Gene expression profile of metastatic human pancreatic cancer cells depends on the organ microenvironment. Cancer Res. 67, 139-148 (2007).
36. Collisson, E. A. et al. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Nat. Med. 17, 500-503 (2011).
37. Weissmueller, S. et al. Mutant p53 drives pancreatic cancer metastasis through cellautonomous PDGF receptor β signaling. Cell 157, 382-394 (2014).
38. Diepenbruck, M. & Christofori, G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr. Opin. Cell Biol. 43, 7-13 (2016).
39. Ye, X. & Weinberg, R. A. Epithelial-mesenchymal plasticity: a central regulator of cancer progression. Trends Cell Biol. 25, 675-686 (2015).
40. Bellomo, C., Caja, L. & Moustakas, A. Transforming growth factor [beta] as regulator of cancer stemness and metastasis. Br. J. Cancer 115, 761-769 (2016).
41. Korpal, M. & Kang, Y. Targeting the transforming growth factor-β signalling pathway in metastatic cancer. Eur. J. Cancer 46, 1232-1240 (2010).
42. Lehuédé, C., Dupuy, F., Rabinovitch, R., Jones, R. G. & Siegel, P. M. Metabolic plasticity as a determinant of tumor growth and metastasis. Cancer Res. 76, 5201-5208 (2016).
43. Nieto, M. A. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 342, 1234850 (2013).
44. Brabletz, T. et al. Variable beta-catenin expression in colorectal cancer indicates a tumor progression driven by the tumor environment. Proc. Natl Acad. Sci. USA 98, 10356-10361 (2001).
45. Chaffer, C. L. et al. Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc. Natl Acad. Sci. USA 108, 7950-7955 (2011).
46. Puisieux, A., Brabletz, T. & Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 16, 488-494 (2014).
47. Chaffer, C. L. et al. Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. Cell 154, 61-74 (2013).
48. Gruber, R. et al. YAP1 and TAZ control pancreatic cancer initiation in mice by direct up-regulation of JAK-STAT3 signaling. Gastroenterology 151, 526-539 (2016).
49. Zhang, W. et al. Downstream of mutant KRAS, the transcription regulator YAP Is essential for neoplastic progression to pancreatic ductal adenocarcinoma. Sci. Signal. 7, ra42-ra42 (2014).
50. Moffitt, R. A. et al. Virtual microdissection identifies distinct tumor-and stroma-specific subtypes of pancreatic ductal adenocarcinoma. Nat. Genet. 47, 1168-1178 (2015).
51. Galvan, J. A. et al. Expression of E-cadherin repressors SNAIL, ZEB1 and ZEB2 by tumour and stromal cells influences tumour-budding phenotype and suggests heterogeneity of stromal cells in pancreatic cancer. Br. J. Cancer 112, 1944-1950 (2015).
52. Bronsert, P. et al. Prognostic significance of Zinc finger E-box binding homeobox 1 (ZEB1) expression in cancer cells and cancer-associated fibroblasts in pancreatic head cancer. Surgery 156, 97-108 (2014).
53. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
54. Eser, S., Schnieke, A., Schneider, G. & Saur, D. Oncogenic KRAS signalling in pancreatic cancer. Br. J. Cancer 111, 817-822 (2014).
55. Ni, T. et al. Snail1-dependent p53 repression regulates expansion and activity of tumour-initiating cells in breast cancer. Nat. Cell Biol. 18, 1221-1232 (2016).
56. Turajlic, S. & Swanton, C. Metastasis as an evolutionary process. Science 352, 169-175 (2016).
57. Caramel, J. et al. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell 24, 466-480 (2013).
58. Denecker, G. et al. Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression. Cell Death Differ. 21, 1250-1261 (2014).
59. Ye, X. et al. Distinct EMT programs control normal mammary stem cells and tumourinitiating cells. Nature 525, 256-260 (2015).
60. Tiwari, N. et al. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell 23, 768-783 (2013).
61. Tran, H. D. et al. Transient SNAIL1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 74, 6330-6340 (2014).
62. Olive, K. P. et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell 119, 847-860 (2004).
63. Jackson, E. L. et al. Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev. 15, 3243-3248 (2001).
64. Hingorani, S. R. et al. Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell 4, 437-450 (2003).
65. Chan, I. T. et al. Conditional expression of oncogenic K-ras from its endogenous promoter induces a myeloproliferative disease. J. Clin. Invest. 113, 528-538 (2004).
66. Novak, A., Guo, C., Yang, W., Nagy, A. & Lobe, C. G. Z/EG, a double reporter mouse line that expresses enhanced green fluorescent protein upon Cre-mediated excision. Genesis 28, 147-155 (2000).
67. Murray, S. A., Carver, E. A. & Gridley, T. Generation of a Snail1 (Snai1) conditional null allele. Genesis 44, 7-11 (2006).
68. Meidhof, S. et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med. 7, 831-847 (2015).
69. Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavare, S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183-2184 (2007).
70. Johnson, W. E., Li, C. & Rabinovic, A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 8, 118-127 (2007).